IMGN ImmunoGen, Inc. Stock Quote

IMGN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.60	Insider Own	0.10%	Shs Outstand	253.26M	Perf Week	-6.53%
Market Cap	778.51M	Forward P/E	-	EPS next Y	-0.74	Insider Trans	0.00%	Shs Float	219.58M	Perf Month	-28.97%
Income	-129.40M	PEG	-	EPS next Q	-0.21	Inst Own	89.20%	Short Float	7.72%	Perf Quarter	-29.39%
Sales	92.20M	P/S	8.44	EPS this Y	-168.30%	Inst Trans	2.52%	Short Ratio	4.14	Perf Half Y	-30.08%
Book/sh	1.21	P/B	2.96	EPS next Y	11.00%	ROA	-32.20%	Target Price	12.00	Perf Year	-44.24%
Cash/sh	2.01	P/C	1.78	EPS next 5Y	-	ROE	-66.60%	52W Range	3.37 - 7.77	Perf YTD	-51.75%
Dividend	-	P/FCF	-	EPS past 5Y	5.70%	ROI	-38.40%	52W High	-54.38%	Beta	1.26
Dividend %	-	Quick Ratio	5.40	Sales past 5Y	26.60%	Gross Margin	-	52W Low	5.19%	ATR	0.33
Employees	106	Current Ratio	5.40	Sales Q/Q	142.70%	Oper. Margin	-	RSI (14)	32.56	Volatility	7.79% 8.20%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	44.30%	Profit Margin	-	Rel Volume	1.63	Prev Close	3.58
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 06 BMO	Payout	-	Avg Volume	4.09M	Price	3.55
Recom	1.90	SMA20	-18.42%	SMA50	-25.46%	SMA200	-37.30%	Volume	1,061,632	Change	-0.98%

Mar-21-22

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$9 → $6

Feb-11-22

Initiated

BMO Capital Markets

Outperform

$18

Dec-01-21

Upgrade

Jefferies

Hold → Buy

$7 → $12

Oct-26-20

Resumed

H.C. Wainwright

Buy

$11

Oct-02-20

Upgrade

Guggenheim

Neutral → Buy

$14

Sep-29-20

Resumed

JP Morgan

Neutral

Dec-17-19

Reiterated

H.C. Wainwright

Buy

$5 → $9

Aug-13-19

Reiterated

H.C. Wainwright

Buy

$4 → $5

May-15-19

Downgrade

Guggenheim

Buy → Neutral

May-06-19

Upgrade

H.C. Wainwright

Neutral → Buy

May-06-19

Upgrade

Cowen

Market Perform → Outperform

Mar-19-19

Downgrade

JP Morgan

Neutral → Underweight

Mar-05-19

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Mar-04-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

Mar-04-19

Downgrade

H.C. Wainwright

Buy → Neutral

$18 → $3.50

Mar-01-19

Downgrade

Piper Jaffray

Overweight → Neutral

$13 → $2.50

Mar-01-19

Downgrade

Jefferies

Buy → Hold

Sep-07-18

Initiated

Piper Jaffray

Overweight

Feb-08-18

Resumed

RBC Capital Mkts

Outperform

$12

Jan-31-18

Initiated

H.C. Wainwright

Buy

$18

May-23-22 07:59AM	ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy MarketWatch
06:30AM	ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review Business Wire
May-10-22 04:30PM	ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference Business Wire
May-06-22 01:30PM	ImmunoGen (IMGN) Q1 2022 Earnings Call Transcript Motley Fool
07:45AM	ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:30AM	ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results Business Wire
May-03-22 08:55AM	10 Best Stocks to Buy Under $20 According to Jeremy Greens Redmile Group Insider Monkey
May-02-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.18%
Apr-28-22 11:18AM	Despite shrinking by US$77m in the past week, ImmunoGen (NASDAQ:IMGN) shareholders are still up 100% over 3 years Simply Wall St.
Apr-21-22 04:01PM	ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results Business Wire
Apr-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.30%
11:23AM	Is ImmunoGen Stock a Bargain After Dropping 39%? Motley Fool
Mar-31-22 04:30PM	ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference Business Wire
Mar-30-22 11:51AM	ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer Zacks
Mar-29-22 06:30AM	ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer Business Wire +11.72%
Mar-21-22 03:07PM	Why These 10 Stocks Are in the Spotlight on Monday Insider Monkey -18.25%
03:00PM	Why Coinbase and Immunogen Led the Nasdaq Lower Monday Motley Fool
08:26AM	Why Are ImmunoGen Shares Trading Lower Today Benzinga
Mar-19-22 07:15PM	ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting Business Wire
Mar-10-22 06:30AM	ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting Business Wire
Mar-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-28-22 10:20AM	ImmunoGen (IMGN) Q4 Earnings and Sales Outpace Estimates Zacks
Feb-27-22 09:16PM	Billionaire Ken Griffin Picks Up These 3 Strong Buy Stocks TipRanks
07:48AM	ImmunoGen, Inc. (NASDAQ:IMGN): Is Breakeven Near? Simply Wall St.
Feb-25-22 07:45AM	ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates Zacks +7.44%
06:30AM	ImmunoGen Reports Recent Progress and 2021 Financial Results Business Wire
Feb-23-22 04:30PM	ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference Business Wire
Feb-16-22 10:58AM	ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B Zacks
10:46AM	Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More Zacks
Feb-15-22 11:19AM	Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B Benzinga
06:40AM	ImmunoGen shares jump 7% premarket on news of license deal with Lilly worth up to $1.7 billion MarketWatch
06:30AM	ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion Business Wire
Feb-10-22 04:01PM	ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results Business Wire
Feb-08-22 08:55AM	Karyopharm Therapeutics (KPTI) Tops Q4 Earnings and Revenue Estimates Zacks
Feb-04-22 04:30PM	ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference Business Wire
03:00PM	Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-31-22 06:30AM	ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs Business Wire +7.82%
Jan-06-22 04:34PM	Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer Investor's Business Daily +6.32%
Jan-05-22 01:38PM	Hall Laurie J Trustee Buys Nestle SA, Trex Co Inc, Tesla Inc, Sells First Republic Bank, ... GuruFocus.com -6.85%
Jan-04-22 10:00AM	ImmunoGen (IMGN) Just Flashed Golden Cross Signal: Do You Buy? Zacks
Jan-03-22 10:36PM	Why Shares of ImmunoGen Jumped 20.3% in December Motley Fool
04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-31-21 06:44AM	We Think ImmunoGen (NASDAQ:IMGN) Can Afford To Drive Business Growth Simply Wall St.
Dec-29-21 04:30PM	ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-14-21 09:01AM	10 Cheap Growth Stocks to Buy According to Billionaire Steve Cohen Insider Monkey -6.17%
Dec-12-21 09:30AM	ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH Business Wire
Dec-11-21 10:19PM	Where Does The Smart Money Stand On ImmunoGen, Inc. (IMGN)? Insider Monkey
06:00AM	3 Under-the-Radar Biotech Stocks to Buy in 2022 Motley Fool
Dec-06-21 04:01PM	ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Dec-02-21 12:00AM	ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock Business Wire +5.76%
Dec-01-21 01:25PM	Why ImmunoGen Stock Is Flying High Today Motley Fool +9.72%
10:06AM	ImmunoGen (IMGN) Surges on Successful Ovarian Cancer Study Zacks
09:22AM	Company News for Dec 1, 2021 Zacks
Nov-30-21 04:33PM	Why ImmunoGen Stock Soared Today Motley Fool +29.89%
04:01PM	ImmunoGen Announces Proposed Public Offering of Common Stock Business Wire
12:48PM	These 2 Nasdaq Biotechs Are Bucking the Market Downtrend Motley Fool
08:15AM	5 Top Stock Gainers for Tuesday Range Across Sectors Despite Omicron Slump TheStreet.com
06:30AM	ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer Business Wire
05:55AM	ImmunoGen Stock Jumps Following Ovarian Cancer Study Results Investing.com
02:11AM	ImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial TheStreet.com
Nov-24-21 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-17-21 04:01PM	ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors Business Wire -6.04%
Nov-16-21 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
06:30AM	ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer Business Wire
Nov-11-21 10:58AM	Implied Volatility Surging for ImmunoGen (IMGN) Stock Options Zacks
Nov-04-21 09:00AM	ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH Business Wire
Nov-01-21 08:03PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
04:04PM	ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag Zacks
12:24PM	ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag Zacks
09:11AM	ImmunoGen's (NASDAQ:IMGN) investors will be pleased with their solid 272% return over the last five years Simply Wall St.
Oct-29-21 05:00PM	ImmunoGen, inc (IMGN) Q3 2021 Earnings Call Transcript Motley Fool
07:45AM	ImmunoGen (IMGN) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:30AM	ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results Business Wire
Oct-22-21 03:00PM	Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-19-21 12:31PM	Hedge Funds Are Crazy About ImmunoGen, Inc. (IMGN) Insider Monkey
Oct-14-21 04:01PM	ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results Business Wire
Oct-01-21 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-22-21 04:01PM	ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors Business Wire
Aug-02-21 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
09:19AM	ImmunoGen (IMGN) Q2 Loss Narrower Than Expected, Revenues Lag Zacks
Jul-30-21 11:30AM	ImmunoGen, inc (IMGN) Q2 2021 Earnings Call Transcript Motley Fool
07:55AM	ImmunoGen (IMGN) Reports Q2 Loss, Misses Revenue Estimates Zacks
06:30AM	ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results Business Wire
Jul-23-21 03:00PM	Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-15-21 04:01PM	ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results Business Wire
Jul-13-21 08:38AM	Hedge Funds Are Crazy About ImmunoGen, Inc. (IMGN) Insider Monkey
Jul-01-21 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-10-21 02:09AM	We Think Shareholders Are Less Likely To Approve A Pay Rise For ImmunoGen, Inc.'s (NASDAQ:IMGN) CEO For Now Simply Wall St.
Jun-09-21 11:30AM	Why Is ImmunoGen (IMGN) Down 8.7% Since Last Earnings Report? Zacks
Jun-01-21 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-20-21 04:30PM	ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference Business Wire
May-19-21 05:00PM	ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status Business Wire
May-10-21 12:00PM	Immunogen Inc (IMGN) Q1 2021 Earnings Call Transcript Motley Fool -11.19%
11:03AM	ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed Zacks
07:45AM	ImmunoGen (IMGN) Reports Q1 Loss, Misses Revenue Estimates Zacks
06:30AM	ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results Business Wire
06:15AM	ImmunoGen, Inc. to Host Earnings Call ACCESSWIRE
May-03-21 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-26-21 04:01PM	ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results Business Wire

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MITCHELL DEAN J	Director	Sep 03	Option Exercise	3.87	83,000	321,400	93,000	Sep 03 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience